Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease

Movement Disorders

Volumn 29, Issue 1, 2014, Pages 61-67

  Lee, Jee Young ^a,b,c   Kim, Jae Min ^b   Ahn, Jeeyun ^a,b   Kim, Han Joon ^b,c   Jeon, Beom S ^b,c   Kim, Tae Wan ^a,b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Optical computed tomography; Parkinson's disease; Retina thickness; Visual hallucination

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE; FEMALE; HUMAN; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA FOVEA; RETINAL NERVE FIBER LAYER THICKNESS; RETINAL THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VERY ELDERLY; VISUAL HALLUCINATION;

OPTICAL COMPUTED TOMOGRAPHY; PARKINSON'S DISEASE; RETINA THICKNESS; VISUAL HALLUCINATION;

AGED; CASE-CONTROL STUDIES; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RETINAL NEURONS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84892928080     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25543     Document Type: Article

References (38)

1. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Mov Disord 2011;26:2387-2395.
2. Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80:276-281.
3. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
4. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 2005;252:1223-1228.
5. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
6. Onofrj M, Bonanni L, Albani G, et al. Visual hallucinations in Parkinson's disease: clues to separate origins. J Neurol Sci 2006;248:143-150.
7. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perception: focused review and a new integrative model. Mov Disord 2005;20:130-140.
8. deMaindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson's disease: a follow-up study. Mov Disord 2005;20:212-217.
9. Frederick JM, Rayborn ME, Laties AM, et al. Dopaminergic neurons in the human retina. J Comp Neurol 1982;210:65-79.
10. Schrier EM, Adam CR, Spund B, Glazman S, Bodis-Wollner I. Interocular asymmetry of foveal thickness in Parkinson's disease [serial online]. J Ophthalmol 2012;728457.
11. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 1990;31:2473-2475.
12. Tatton WG, Kwan MM, Verrier MC, et al. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res 1990;527:21-31.
13. Altintas O, Iseri P, Ozkan B, Caglar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol 2008;116:137-146.
14. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson's disease. Arch Ophthalmol 2009;127:737-741.
15. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vis Res 2004;44:2793-2797.
16. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011;17:431-436.
17. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol 2010;4:1427-1432.
18. Albrecht P, Muller AK, Sudmeyer M, et al. Optical coherence tomography in parkinsonian syndromes [serial online]. PLoS One 2012;7:e34891.
19. Spund B, Ding Y, Liu T, Selesnick I, Glazman S, Shrier EM, Bodis-Wollner I. Remodeling of the fovea in Parkinson disease. J Neural Transm 2013;120:745-753.
20. Garcia-Martin E, Satue M, et al. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. Ophthalmology 2012;119:2161-2167.
21. Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, Kanakis M, Koutsandrea C. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur J Ophthalmol 2011;21:24-29.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992:55:181-184.
23. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
24. Mosimann UP, Collerton D, Dudley R, et al. A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry 2008;23:712-718.
25. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
26. Verhulst E, Vrijghem JC. Accuracy of intraocular lens power calculations using the Zeiss IOL master. A prospective study. Bull Soc Belge Ophtalmol 2001;281:61-65.
27. Bagci AM, Shahidi M, Ansari R, et al. Thickness profiles of retinal layers by optical coherence tomography image segmentation. Am J Ophthalmol 2008;146:679-687.
28. Forte R, Cennamo GL, Finelli ML, de Crecchio G. Comparison of time domain Stratus OCT and spectral domain SLO/OCT for assessment of macular thickness and volume. Eye (Lond) 2009;23:2071-2078.
29. Budenz DL, Anderson DR, Varma R, et al. Determinants of normal retinal nerve fiber layer thickness measured by Stratus OCT. Ophthalmology 2007;114:1046-1052.
30. Lee JY, Lee EK, Lim JY, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009;24:1803-1810.
31. Gallagher DA, Parkkinen L, O'Sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 2011;134:3299-3309.
32. Jindahra P, Petrie A, Plant GT. Retrograde trans-synaptic retinal ganglion cell loss identified by optical coherence tomography. Brain 2009;132:628-634.
33. Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. Expert Rev Neurother 2007;7:1731-1750.
34. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004;63:1409-1416.
35. Abbott EJ, Connor GB, Artes PH, Abado RV. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Investigative Ophthalmol Vis Sci 2007;48:1416-1423.
36. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007;14:750-756.
37. Boecker H, Ceballos-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-988.
38. Bodis-Wollner I. Foveal vision is impaired in Parkinson's disease. Parkinsonism Relat Disord 2013;19:1-14.